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Amyloid seeds are nanometer-sized protein particles that accelerate
amyloid assembly as well as propagate and transmit the amyloid
protein conformation associated with a wide range of protein
misfolding diseases. However, seeded amyloid growth through tem-
plated elongation at fibril ends cannot explain the full range of
molecular behaviors observed during cross-seeded formation of am-
yloid by heterologous seeds. Here, we demonstrate that amyloid
seeds can accelerate amyloid formation via a surface catalysis
mechanism without propagating the specific amyloid conforma-
tion associated with the seeds. This type of seeding mechanism is
demonstrated through quantitative characterization of the cross-
seeded assembly reactions involving two nonhomologous and un-
related proteins: the human Aβ42 peptide and the yeast prion–
forming protein Sup35NM. Our results demonstrate experimental
approaches to differentiate seeding by templated elongation from
nontemplated amyloid seeding and rationalize the molecular
mechanism of the cross-seeding phenomenon as a manifestation
of the aberrant surface activities presented by amyloid seeds as
nanoparticles.
protein aggregation and assembly | Sup35 yeast prion protein | amyloid β
peptide | atomic force microscopy | Saccharomyces cerevisiae
Amyloid particles are associated with numerous neurode-generative and/or age-related human disease such as Alz-
heimer’s disease, Huntington’s disease, Parkinson’s disease, and
type 2 diabetes mellitus (1, 2). The slow nucleation-dependent
process that converts normally soluble protein or peptide precur-
sors into their amyloid conformation (3) can be bypassed through
the addition of preformed amyloid particles, the seeds. This phe-
nomenon, which effectively accelerates amyloid growth and prop-
agates the amyloid conformation, is called seeding. The seeded
growth of amyloid, as well as transmissible forms of amyloid known
as prions, via the templated addition of monomer units or small
oligomers to the ends of preformed fibril seeds (4–6) is known as
fibril elongation (Fig. 1A).
Elongation at amyloid fibril ends has long been viewed as the
sole mechanism of seeded amyloid growth, in which the specific
amyloid conformation encoded in the seeds is propagated upon
the addition of new monomers or small oligomers at fibril ends
(4, 7). This mechanistic assumption has been, for example, ap-
plied in attempts to propagate patient-derived amyloid material
for structural studies and has been challenged through evidence
to suggest that the structure of the seeds does not necessarily
propagate though seeded growth (8). Furthermore, a protein
can form amyloid in an accelerated manner upon addition of
amyloid seeds preformed with precursors of very different or
even completely nonhomologous amino acid sequences (9). The
molecular mechanism of this phenomenon, often termed “cross-
seeding,” remains unresolved, because the current models for
the fibril elongation growth mechanism cannot explain the full
range of molecular behaviors observed during amyloid cross-
seeding.
For mammalian disease-associated amyloidogenic proteins,
cross-seeding activity may be a key process promoting a synergy
between amyloid associated disorders. A number of studies have
demonstrated that two different amyloidogenic disorders may
arise in the same individual and, in so doing, impact on the re-
spective occurrence and pathologies of the disorders (10, 11).
For example, it has been proposed that cross-seeding between
Aβ and α-synuclein (12) and Aβ42 and IAPP (13) might con-
tribute the observed statistical correlations between the oc-
currence of Alzheimer’s disease and Parkinson’s disease or type
2 diabetes, respectively (14–16). Thus, understanding the funda-
mental nature of the molecular crosstalk between amyloidogenic
disease-associated proteins and the underlying molecular mecha-
nism will provide essential clues to a better understanding of how
these diseases originate, propagate, and even transmit between
individuals.
Amyloid fibrils are protein filaments with monomeric units
arranged in the characteristic cross-beta molecular architecture
held together by noncovalent interactions and hydrogen bonds
parallel to the fibril axis (17). The fibrils are usually in the order of
10 nm in width, and amyloid seeds are typically small amyloid fibril
fragments often less than 100 nm in length. Thus, amyloid seeds
are bona fide nanoparticles (i.e., particulate materials with indi-
vidual particle dimensions in the order of or below 100 nm for at
least two out of three spatial directions) (18). Like any type of
nanoparticle, the small sizes of amyloid seeds confer these particles
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with high surface-to-volume ratios. These surfaces are frequently
capable of interacting with molecules in their surroundings and can
be coated with a corona of proteins and other macromolecules in
addition to ions and small molecules in biological environments
(19, 20).
The surfaces of amyloid seeds contain active sites where growth
by elongation takes place at their termini, as well as surfaces par-
allel to the cross-beta hydrogen bonds that have previously been
shown to be exceptionally active in catalyzing heterogeneous nu-
cleation of new amyloid in what is called “secondary nucleation” as
is observed in the formation of Aβ amyloid (21). Thus, amyloid
seeds, in addition to promoting the propagation of the specific
amyloid conformation encoded by the monomeric units at their
elongation active sites through templated growth at fibril ends, may
also be able to catalyze generic surface-mediated assembly like any
nanoparticle and accelerate the formation of heterologous amyloid
through catalyzing heterogeneous nucleation.
In order to test whether such a general surface-catalyzed mech-
anism can explain and rationalize the molecular mechanism of
amyloid cross-seeding and to show that the seeding and templating
activities of amyloid seeds can potentially be mechanistically
uncoupled, we investigated the cross-seeding interactions between
two unrelated amyloidogenic proteins: human Aβ42 that is asso-
ciated with Alzheimer disease (2) and the amyloid-forming protein
Sup35NM that is a component of a prion-based epigenetic switch
in the yeast Saccharomyces cerevisiae (7). We have chosen these
two proteins, because being from two organisms at different ends
of the evolutionary spectrum, they do not coexist in the same bi-
ological context. Sup35 (eRF3) is present in human cells but lacks
the N-terminal and middle (NM) regions critical for amyloid
formation and propagation (7). Furthermore, Aβ and Sup35NM
have low sequence similarities (SI Appendix, Fig. S1 A and C)
and dissimilar amino acid compositions (SI Appendix, Fig. S1B)
as expected from two functionally unrelated proteins. The am-
yloid aggregation mechanism of human Aβ42 has been studied in
considerable detail (21), revealing an assembly mechanism domi-
nated by secondary nucleation accelerated by preexisting fibril
surfaces. Sup35, on the other hand, is regarded as a functional
amyloid, and its assembly mechanism reveals a strong compo-
nent of templated elongation (4, 7). Here we demonstrate that
these two unrelated proteins are capable of cross-seeding each
other (i.e., the presence of the amyloid seed of one protein is
capable of accelerating amyloid formation of the other protein
despite their dissimilar sequence, structure, and biological origins).
We also show that these heterologous interactions are “asymmet-
ric” (22) (i.e., the kinetic effect of the seeds is different with respect
to amyloid assembly of each other). We demonstrate that these
cross-seeding interactions are mass sensitive but not particle num-
ber sensitive. In addition, by exploiting the well-characterized prion
phenotype [PSI+] associated with the amyloid state of Sup35 pro-
tein, we demonstrate the phenotypic outcome on cells propagating
either the self-seeded or cross-seeded Sup35NM prion particles
in vivo. Together, our in vitro and in vivo results demonstrate that
amyloid seeds are nanoparticles with active surfaces that can me-
diate the cross-seeding of heterologous amyloid through generic
surface-catalyzed reactions, resulting in accelerated amyloid growth,
without structural templating of the precise amyloid conformation
encoded in the seeds.
Fig. 1. Schematic illustration of the molecular processes in the amyloid life cycle together with experimentally testable hypotheses. (A) The amyloid lifecycle
with key sites and surfaces for templated growth and secondary nucleation highlighted in red and purple, respectively. (B–E) Comparison of a seeding
mechanism based on templated growth at fibril ends and a seeding reaction with fibril growth promoted by a fibril surface-catalyzed nucleation mechanism.
Experimentally testable and comparable features for each prediction are highlighted by red or purple glow. (B) Prediction I: A surface-catalyzed seeding
reaction is nucleation dependent and, therefore, is slow, with a lag phase that cannot be readily eliminated by the seeds, compared to a faster seeding
reaction through elongation. (C) Prediction II: The number of active sites for seeding through templated elongation (red) depends on the number of particles,
while the number of active surfaces for surface-catalyzed seeding mechanism (purple) depends on the protein mass concentration. (D) Prediction III: The
morphology of the fibrils newly formed by surface-catalyzed seeding does not need to be the same as that of the seeds. (E) Prediction IV: Indistinguishable
fibril morphology and biological activity is produced from the same monomers under the same conditions independently of the seeds used for a surface-
catalyzed seeding reaction. All arrows represent multiple dynamic and reversible steps along the lifecycle and the thickness of the arrows illustrate typical
relative magnitudes of the rates involved in each of the processes.
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Both Templated Elongation and Surface-Catalyzed NucleationMechanisms
Can Promote Accelerated Amyloid Assembly, but Each Produce Different
Seeding Behaviors. Seeding is a process defined as the acceleration of
amyloid formation in the presence of seeds. To test whether amyloid
seeds are nanoparticles that can accelerate the formation of new
heterologous amyloid through nontemplated surface-catalyzed as-
sembly reactions, we first examined in detail the mechanistic dif-
ferences between templated seeding reactions by elongation versus
the nontemplated surface-catalyzed seeding reactions (Fig. 1 B–E).
In so doing, we sought to establish whether the addition of seeds can
accelerate amyloid assembly either through templated growth by
elongation at fibril ends (left schematic in Fig. 1 B–E) or surface-
catalyzed nucleation of new amyloid (right schematic in Fig. 1 B–E)
and if these two pathways can be distinguished experimentally. As
illustrated in Fig. 1 B–E, if given amyloid particles are capable of
seeding or cross-seeding the formation of new amyloid through a
surface-catalyzed nucleation mechanism instead of templated elon-
gation, one would predict a number of differences in the molecular
and kinetic behaviors of the seeded reactions that should be
distinguishable experimentally.
Firstly, the presence of active surfaces should reduce but not
eliminate the nucleation barrier for assembly (Fig. 1B, prediction
I), since surface-catalyzed assembly would still be a nucleation-
dependent process. Consequently, such a reaction would still go
through a slow nucleation phase, albeit faster compared to nu-
cleation in the absence of surface catalysis (SI Appendix). Thus,
the addition of seeds active in surface catalysis of nucleation would
only be capable of reducing the length of the lag phase but not
eliminate the lag phase entirely as would be observed with seeding
reactions that proceed through templated elongation. Secondly,
the number of growth active sites for templated elongation is only
present at fibril ends and therefore relates to the particle con-
centration of the seed particles. On the other hand, surfaces along
the seeds that potentially can catalyze heterogeneous nucleation
such as secondary nucleation or surface-catalyzed seeding events
should depend on the total length of the particles, which is in turn
proportional to the mass or monomer equivalent concentration of
seeds and not the number concentration of the seed particles (SI
Appendix and Fig. 1C, prediction II). Thirdly, if new amyloid is
formed through seeding by a surface-catalysis mechanism, then
the fibril morphology of the newly formed fibrils does not need to
be the same as the morphology of the seeds (Fig. 1D, prediction
III). Finally, if newly formed amyloid assembles through seed
surface-catalyzed reactions, then their morphology and the bio-
logical response they elicit should only be linked to their monomer
precursors and the conditions applied but not the seeds (Fig. 1E,
prediction IV). These four experimentally testable differences
were therefore used to rationalize whether amyloid particles can
act as broad-spectrum seeds that are capable of accelerating the
formation of new and heterologous amyloid primarily due to the
activities of their surfaces in the same way as the action of
nanoparticles.
Self-Seeded Growth of Both Aβ42 and Sup35NM Amyloid Fibrils
Proceeds through Templated Fibril Elongation. To characterize the
heterologous seeding potential of amyloid particles, we chose to
investigate the self-seeding and cross-seeding interactions between
two unrelated proteins: human Aβ42 and yeast Sup35NM. These
two amyloid-forming proteins are native to different organisms, do
not naturally coexist in the same biological context, and do not share
any known evolutionary linkages. Furthermore, human Aβ is asso-
ciated with Alzheimer’s disease known to be statistically correlated
with the occurrence of a number of other amyloid-associated dis-
eases (14–16), while the full-length Sup35 protein can become a
transmissible prion and can be regarded as a functional amyloid (7).
These two proteins also have low sequence similarities (SI Appendix,
Fig. S1C) and are dissimilar in terms of size, charge, amino acid
composition (SI Appendix, Fig. S1), and fibril structures. Therefore,
each of these two proteins should not be able to grow onto fibril
seeds preformed by the other protein through templated assembly.
Hence, they provide ideal and unbiased tests of the heterologous
seeding capabilities of amyloid particles.
We first generated fibrillar seed particles of Aβ42 and
Sup35NM (here called Aβ42s and Sup35NMs, respectively)
in vitro by incubating the monomeric precursors of respective
amyloid (here called Aβ42m and Sup35NMm, respectively) un-
der common fibril growth solution conditions as both proteins form
amyloid fibrils under physiological pH. To generate Aβ42s fibril
particles, a synthetic Aβ42 peptide (Bachem, Germany) was used.
The peptide samples were dissolved in 6M GdnHCl at pH10, and
Aβ42m monomers were purified by gel filtration using a Superdex
75 column immediately prior to assembly to ensure the generation
of reproducible and high-quality Aβ42s amyloid seeds (23, 24).
Monomeric Sup35NMm protein was produced recombinantly in
Escherichia coli and assembled as described previously (25). Aβ42s
and Sup35NMs fibrils were subsequently dispersed by brief con-
trolled sonication (Materials and Methods) and imaged using atomic
force microscopy (AFM). Interestingly, the Aβ42s particles were
apparently less resistant to sonication compared to Sup35NMs
particles. Consequently, 1 s of controlled sonication was sufficient to
disperse the Aβ42s fibrils for imaging, while at least 5 s of controlled
sonication was required to disperse Sup35NMs fibrils prior to im-
aging. Fig. 2A shows AFM images of Aβ42s and Sup35NMs fibril
seeds imaged by AFM.
Fig. 2. AFM images of Aβ42s and Sup35NMs fibril seeds. (A) AFM images of initial samples of Aβ42s and Sup35NMs seeds after brief controlled sonication to
disperse the fibrils. (B) AFM images of Aβ42s and Sup35NMs seeds after a different length of controlled sonication. For all images, the insets show 4
times–magnified areas for each image. (Scale bars, 2 μm and 500 nm.) The length of sonication is indicated in the lower right corner in all images.
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Controlled sonication is a method commonly used to fragment
amyloid fibrils for seed generation. To validate controlled soni-
cation as being capable of generating Aβ42s and Sup35NMs seed
samples with different particle concentrations, while retaining
their respective original mass concentrations, the seed samples were
subjected to controlled sonication for different periods of time. As
shown in Fig. 2B, for Sup35NMs, increasing the sonication time
from 5 s to 300 s decreased the lengths of the seed particles and
therefore increased the particle concentration as expected and
previously seen (25). The same effect of decay in particle lengths
and a rise in particle concentration as sonication time increased
from 1 s to 60 s was also seen for Aβ42s particles (Fig. 2B). As
previously observed, the Aβ42s particles were less resistant to son-
ication compared to Sup35NMs particles, with 60 s of controlled
sonication generating a large number of small nanoparticles less
than 100 nm as seen using AFM (Fig. 2B). Additional sonication
did not further alter their size distribution noticeably as would be
expected due to their already small sizes (26, 27). To further con-
firm the quality the Aβ42s and Sup35NMs seed samples, dynamic
light scattering (DLS) was performed on these seed samples after
controlled sonication (Materials and Methods). As shown in SI Ap-
pendix, Fig. S2, the DLS experiments show that both the Aβ42s and
Sup35NMs seed samples consisted of a distinct distribution of
fragmented fibrils without the presence of any major secondary
particle distributions. Thus, the AFM and DLS experiments to-
gether confirmed the presence of high-quality seed samples for both
Aβ42s and Sup35NMs formed under the same solution conditions.
To confirm the ability of Aβ42s and Sup35NMs particles to
seed the formation of new amyloid, we performed a series of
seeded fibril growth kinetic assays monitored using the fluorescence
of the amyloid-specific Thioflavin T (ThT) dye in a 96-well plate
format, involving both Aβ42m and Sup35NMm each seeded by
seeds formed from monomers of the same sequence (i.e., self-
seeding). The kinetic profiles of amyloid growth were mapped as a
function of low seed concentrations ranging from 0.1 to 5% to
determine the parameters of respective seeded growth and their
dependence on seed particle concentration (Fig. 3 A and D). Sub-
sequently, we extracted and analyzed two parameters characteristic
for the amyloid assembly kinetics (SI Appendix, Fig. S3); the length
of the lag phase (tlag, compared in Fig. 4 A–D) and the initial slope
(k0, compared in Fig. 5 A and B) from each reaction trace. For
Sup35NM fibril seeds (Sup35NMs) self-seeded with Sup35NM
monomers (Sup35NMm), the presence of 0.1 to 5% monomer
molar equivalent seeds in a growth reaction with 10 μM total
monomer equivalent concentration dramatically shortened or
eliminated the lag-phase in all cases. Importantly, as seen in Fig. 4D,
as little as 0.5 to 1% monomer molar equivalent of the seeds was
sufficient to eliminate the lag phase by reducing tlag to 0 h. This
behavior is entirely consistent with templated monomer addition to
the preformed fibril-seed ends acting as a dominant mechanism of
the elongation growth (4, 7). Seeding efficiency also increased with
higher added particle concentrations either through increased
monomer molar equivalent seeds or through increased sonication at
the same monomer molar equivalent (Fig. 4D). As seen in Fig. 5A
(red lines), the initial slope of seeded growth curves is directly
proportional to particle concentration, which in turn is proportional
to the number of active growth sites for elongation at fibril-ends at
low particle concentrations. At high concentrations, the elongation
process can become saturated as also seen in other amyloid systems
(e.g., ref. 28). Global analysis of the kinetic traces (SI Appendix, Fig.
S4D and Table S1) further confirmed that a model describing a
mechanism dominated by elongation fitted the data. Therefore, the
data demonstrate that the self-seeded growth of Sup35NM pro-
ceeds through templated elongation at fibril ends as expected (4).
Similarly to Sup35NM, assembly of Aβ42 monomers (Aβ42m)
was significantly accelerated by the addition of as little as 0.1%
preformed Aβ42 fibril-seeds (Aβ42s). The lag-phase was eliminated
in the presence of as low as ∼1% monomer molar equivalents or
more of seeds (Fig. 4A). Increasing the seed particle concentration
also increased the initial slope of the growth reactions in the same
linear manner at low seed particle concentrations as seen with
Sup35NM and other amyloid-forming systems (Fig. 5B, blue lines).
Furthermore, increasing the particle concentration at constant molar
equivalent monomer concentration of seeds by sonication also
shortened the lag-phase, demonstrating that the seeding reaction is
dependent on the particle concentration of the seeds (Fig. 4A). As
with self-seeded Sup35NMm assembly, global analysis of the kinetic
traces (SI Appendix, Fig. S4A and Table S1) confirmed that a model
describing a mechanism dominated by elongation also fitted the data
of self-seeded Aβ42m assembly. In this case, the globally fitted
model shows a minor systematic deviation when compared to the
experimental nonseeded kinetic traces (dark blue traces in Fig. 3A)
that displayed a shallow slope in their lag phase baselines. This is
likely due to residual Aβ42 aggregates in the monomer protein
fraction used at the start of the experiment (29). However, the
globally fitted model with an elongation-dominated mechanism fully
reproduced the kinetic effect of seeding in eliminating the lag phase
at the low-seed concentrations used. Therefore, the self-seeded
growth of Aβ42 amyloid also displayed all the hallmarks of a seed-
ing mechanism dominated by templated elongation at fibril-
seed ends.
Growth of Aβ42 Amyloid Fibrils Is Accelerated by Sup35NM Seeds in a
Mass Concentration–Dependent, but Not Particle Number–Dependent,
Manner. Having established the self-seeded reactions proceed
through templated elongation at fibril-seed ends for both Aβ42
and Sup35NM, we next investigated whether the seeds formed from
these two unrelated amyloidogenic proteins are able to accelerate
the amyloid forming reaction of each other in cross-seeded reac-
tions. First, we investigated the growth kinetics of Aβ42m assembly
Fig. 3. Kinetics traces of seeded amyloid formation monitored by ThT
fluorescence. Typical normalized traces of (A) monomers of Aβ42 (Aβ42m)
self-seeded by Aβ42 seeds (Aβ42s) or (B) by Sup35NM seeds (Sup35NMs) as
well as (C) Sup35NM monomers (Sup35NMm) seeded by Aβ42 seeds (Aβ42s)
or (D) self-seeded by Sup35NM seeds (Sup35NMs). For each monomer–seed
combination, at least nine replicate reaction traces from three independent
experiments containing reactions with different ratios (0 to 5% mol/mol) of
seeds to monomer ratio added were collected, and three to five replicate
traces are shown for each reaction for clarity. Both Aβ42s and Sup35NMs
used were sonicated for 60 s.
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in the presence of Sup35NMs seeds. In a series of fibril growth
kinetic assays monitored using ThT fluorescence (Fig. 3B), the
addition of heterologous seeds (in this case, the unrelated
Sup35NMs) in low concentrations (5% or less monomer molar
equivalents) to monomer solutions of Aβ42 was able to statistically
significantly reduce the lag time of the Aβ42 amyloid formation
(Fig. 4B). These experiments show that Sup35NMs can act as seeds
that accelerate amyloid formation of Aβ42, albeit with less effi-
ciency in reducing the duration of the lag phase than Aβ42s. In-
terestingly, the addition of 5% monomer molar equivalents of
Sup35NMs failed to eliminate the lag phase of Aβ42 amyloid
growth (tlag > 0 in Fig. 4B and k0 ∼ 0 in Fig. 5A, blue lines). This
finding is not consistent with a templated elongation mechanism but
is consistent with Sup35NMs being nanoparticles that act as generic
seeds through surface-catalyzed heterogeneous nucleation, because
the slow nucleation events should still occur (Fig. 1, prediction I).
Global analysis of these cross-seeded kinetic traces (SI Appendix,
Fig. S4B) also confirm that the data are consistent with a surface-
catalyzed heterogeneous nucleation mechanism.
If the nucleation events catalyzed by the large available surface
area of Sup35NMs (and not active growth sites at fibril-ends)
directs the shortening of the lag-phase in these heterologous
cross-seeded reactions, then the number of free ends that are
responsible for the templating process should exert no significant
effect on the efficiency of seeding (Fig. 1, prediction II) as long as the
monomer equivalent concentration (equivalent to the mass con-
centration of seeds) is maintained. We tested this prediction by
adding Sup35NMs sonicated to different extents and therefore
should have identical monomer mass concentration but different
seed particle concentrations (25) to the Aβ42m solutions (Fig. 2B).
Remarkably, adding an identical mass of Sup35NMs seeds that were
subjected to less time of sonication did not significantly increase the
length of lag-phase of Aβ42 assembly, nor did the length of lag phase
decrease significantly when identical mass of Sup35NMs seeds,
which were subjected to a greater sonication time, were added. Thus,
changing the particle concentration of Sup35NMs while maintaining
identical protein mass concentration of seeds produced no signifi-
cant effects on the length of lag-phase of Aβ42 fibril forming reac-
tions (Fig. 4B). These results provided kinetic evidence to support
that Sup35NMs, while biologically and structurally unrelated to
Aβ42s, are able to accelerate the amyloid formation of Aβ42 by
acting as nanoparticles that provide their surface for catalyzing Aβ42
amyloid formation.
Growth of Sup35NM Amyloid Fibrils Is Also Accelerated by Aβ42 Seeds
but Not to the Same Extent. We next tested whether Aβ42s were
also able to accelerate the amyloid assembly of Sup35NMm in the
opposite heterologous cross-seeded reaction. As before, we incu-
bated Sup35NMm solutions in the presence of various amounts of
Aβ42s and monitored the fibril growth kinetic using ThT fluo-
rescence (Fig. 3C and SI Appendix, Fig. S4C). For Sup35NM
amyloid formation, Aβ42s was also able to significantly shorten,
but not eliminate, the length of the lag phase. However, this lag
phase-shortening effect was reduced in magnitude compared with
the other three reaction pairs analyzed, with around a 25% reduc-
tion in the length of the lag phase upon addition of 5% monomer
molar equivalents of Aβ42s compared to unseeded reactions (Figs.
4C and 5B, red lines). Similar to the effect of Sup35s on Aβ42m
assembly, a change in particle concentration without a change in
monomer equivalent mass concentration of Aβ42s by varying soni-
cation time for Aβ42s led to no significant effect on the length of the
lag phase of Sup35NMm assembly. These experiments indicate that
Aβ42s particle surfaces are also able to accelerate the nucleation of
Sup35NM amyloid fibrils, but the efficiency is less compared to the
Fig. 4. The relative reduction in the length of lag phase upon addition of seeds compared to unseeded amyloid formation. The relative length of the lag
phase (tlag) values of (A) Aβ42 monomers (Aβ42m) self-seeded by Aβ42s or (B) by Sup35NMs as well as (C) Sup35NM monomers (Sup35NMm) seeded by Aβ42s
or (D) self-seeded by Sup35NMs seeds are shown as ratio to tlag values of respective unseeded reactions (tlag,0). For each protein pair, seeding reactions were
performed with varying concentration of seeds sonicated to 60 s as well as varying degrees of sonication at 1% seeds added as indicated by varying sized
symbols (small, medium, and large sonication symbols denote for Aβ42s 1 s, 5 s, and 60 or 300 s of sonication, and for Sup35NMs, 5 s, 60 s, and 300 s of
sonication, respectively). The tlag values were extracted from the kinetics traces using the method illustrated in SI Appendix, Fig. S3. The distribution of tlag
values for each experiment are shown as box plots with the thick line representing the median, and each bar represents the data from at least nine replicate
reactions from three independent experiments. One-way ANOVA with Tukey’s Honestly Significant Difference Procedure was carried out for statistical
multiple pair-wise comparison. The “*”, “***”, and “n.s.” labels denote when the sample mean relative tlag values of the compared pairs are significantly
different with P value less than 0.05, P value less than 0.001, or not significant with P value more than 0.05, respectively.
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effect of Sup35NMs surfaces on Aβ42m assembly (compare Fig. 4 B
and C). This asymmetry is consistent with the fact that the efficiency
of surface-catalyzed heterogeneous nucleation mechanism for cross-
seeding is dependent on the physical and chemical properties of the
seed surfaces in the same way as any nanoparticle interaction
with biology.
Sup35NM Amyloid Formed through Self-Seeding and Cross-Seeding
with Aβ42s Seeds Display Indistinguishable Fibril Morphology and
Induce Identical Prion Phenotypes In Vivo. If the mechanism of
heterologous cross-seeding involves generic seeding through
heterogeneous nucleation catalyzed by surfaces of seeds as
nanoparticles, then the amyloid fibril morphology of the newly
grown amyloid does not need to be the same as that of the seeds
(Fig. 1, prediction III). The morphology and the biological prop-
erties of the newly grown amyloid may also be the same under the
same solution conditions and independently of whether they were
formed through homologous self-seeding or heterologous cross-
seeding (Fig. 1, prediction IV). To test these structural predic-
tions, we used AFM to analyze Sup35NM fibrils formed in two
seeded reactions, either self-seeded with preformed Sup35NMs
fibrils or cross-seeded with Aβ42s fibrils (Fig. 6A). The morphology
of Sup35NM fibrils grown by cross-seeding with Aβ42s (Fig. 6A),
characterized by the height distribution (Fig. 6B), was strikingly
different compared to that of Aβ42s. The fibril heights of Aβ42-
seeded Sup35NM fibrils were significantly different to those of the
Aβ42s but indistinguishable to self-seeded or de novo grown
Sup35NM fibrils. This is consistent with the specific amyloid con-
formation of Aβ42s seeds not being imposed on the newly formed
Sup35NM fibrils, confirming the structural prediction III (Fig. 1D,
prediction III). Importantly, because fibrils in these heterologous
cross-seeded reactions were indistinguishable from those formed
from self-seeding with Sup35NMs or from de novo assembly of
Sup35NMm (Fig. 6A), and the height distributions for all these
samples were also not significantly different from each other
(Fig. 6B), these fibril populations must be formed mainly due to the
monomer sequence and the solution condition, in agreement with the
structural prediction IV (Fig. 1E, prediction IV). Taken together,
these results support the hypothesis that the heterologous seeds in
this case merely accelerated the kinetics of amyloid formation without
passing on its precise conformation by a lack of templating.
Similar to the mammalian prion protein PrP that can exist in
structurally different prion conformation and distinct “strains” (30),
the yeast [PSI+] prion linked to the amyloid form of the Sup35
protein can also exist as different conformational “strains” gener-
ating phenotypically distinct but stable [PSI+] “variants” (31). The
phenotype linked to a given [PSI+] variant (i.e., a defect in trans-
lation termination leading to stop codon read-through) reflects the
strength of the underlying biological prion activity and is based on
the different mechanical and structural properties of the Sup35
assemblies in that variant (31–33). The phenotype imposed by a
[PSI+] variant can be readily detected and visualized using a well-
established colorimetric assay utilizing S. cerevisiae strains carrying
the ade1-14 nonsense mutant allele. In these ade1-14 yeast strains,
the presence of the [PSI+] prion leads to suppression of the ade1-
14-linked phenotype (i.e., red colonies requiring adenine [Ade]) to
restore the wild-type Ade+ phenotype with colony color ranging
from pink to white depending on the specific [PSI+] variant (31, 34,
35). Thus, the [PSI+] phenotype provides a sensitive in vivo test of
prediction IV (Fig. 1E, prediction IV, i.e., whether fibrils formed
from self-seeding with Sup35NMs were comparable to those
formed by heterologous cross-seeded reactions through generic
surface catalyzed action of Aβ42s seeds as nanoparticles).
Nonseeded (i.e., de novo grown from Sup35NMm), self-seeded,
and Aβ42s cross-seeded Sup35NM particles were introduced into
spheroplasts of red colony forming prion-free [psi−] yeast cells by
protein transfection (Materials and Methods and ref. 25). The
phenotypes of the resulting transfected colonies were initially
assessed by plating onto a rich growth medium (1/4YEPD; Ma-
terials and Methods) and onto a defined medium lacking adenine.
To establish whether white Ade+ transfectants induced by each of
the introduced amyloid samples contained the [PSI+] prion, these
colonies were then replica-plated onto 1/4YEPD containing 3 mM
GdnHCl. At this low concentration, GdnHCl inhibits [PSI+]
propagation leading to a loss of the prion form and restoration of
the [psi−] red, Ade− phenotype (Fig. 6C). Protein transfection of a
[psi−] yeast strain with the various Sup35NM amyloid particles,
either grown from different seeds or no seeds, resulted in the
generation of indistinguishable number and phenotypical pattern
of [PSI+] transfectants, with the majority showing a “strong” white
Ade+ phenotype while the remaining 15% had a “weak” [PSI+]
phenotype (i.e., pink or dark pink Ade+ colonies) (Fig. 6D).
These in vivo studies support the conclusion that the fibril
particles have an indistinguishable morphology independent of
the seeds they were exposed to and that they also give rise to
the same biological phenotype, which in turn is sensitive to
small conformational difference in the amyloid architecture
(32, 36). Therefore, the seeding of Sup35NMm monomers with
heterologous Aβ42s amyloid seeds did not generate amyloid
particles that affect the conformation of Sup35, which was
faithfully transmitted and propagated in vivo. This finding agrees
with the structural predictions III and IV (Fig. 1 D and E, pre-
dictions III and IV) for a cross-seeding mechanism involving
generic heterogeneous nucleation catalyzed by surfaces of seeds as
nanoparticles.
Aβ Amyloid Fibril Seeds Are Capable of Inducing [PSI+] Phenotype
upon Transfection into Yeast Cells. The in vitro kinetics studies
show that the surfaces of Aβ42s seeds can interact and cross-seed
the formation of Sup35NM amyloid fibrils by acting as nano-
particles that promote surface-catalyzed interactions (Figs. 3C,
Fig. 5. The increase of the initial slope of the kinetic traces as function of
increasing percentage of seeds. The average initial slope values (k0)
extracted from the ThT traces (Fig. 3) of (A) Aβ42 monomers (Aβ42m) or
Sup35NM monomers (Sup35NMm) seeded by Sup35NMs seeds as well as (B)
seeded by Aβ42s seeds are shown as “+” with error bars representing the SE
of mean. The k0 values were extracted from the kinetics traces using the
method illustrated in SI Appendix, Fig. S3. The error bars for some reactions
with low k0 values are not visible due to being smaller than the symbol.
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4C, and 5B). To test whether heterologous Aβ42s nanoparticles
introduced into a [psi−] yeast cell can trigger the appearance of
the Sup35-based [PSI+] prion in vivo, we next transfected yeast
spheroplasts prepared from a [psi−] ade1-14 yeast strain with the
in vitro–assembled Aβ42s particles. Approximately 2% of the
Aβ42s-transfected colonies analyzed contained a mixture of red
and white colony-forming cells (Fig. 7A) suggestive of a low rate
of prion conversion in the primary transfected cell. When these
mixed red/white colony-forming transfectants were restreaked
onto fresh 1/4YEPD medium, the rare white colonies that
formed displayed all of the properties associated with the pres-
ence of the [PSI+] prion (i.e., a stable white colony phenotype on
1/4YEPD medium; growth on selective medium lacking adenine;
and stable loss of the white phenotype when grown in the
Fig. 6. Sup35NM amyloid fibrils formed through self-seeding, cross-seeding using Aβ42s seeds, or unseeded reactions are morphologically and biologically
indistinguishable. (A) Typical AFM images of Sup35NM fibrils formed through self-seeding (Upper), cross-seeding using Aβ42s (Middle), or unseeded (Lower)
reactions. Scale bar indicates 2 μm in all three images. (B) The distribution of fibril heights, characteristic of their widths, for the Sup35NM fibrils were
extracted from the images in A and represented as violin plots. The thick line in each distribution represents the mean height. The “***” and “n.s.” labels
denote when the mean height values of the compared sample pairs are significantly different as indicated by one-way ANOVA with Tukey’s Honestly Sig-
nificant Difference Procedure in which P value is less than 0.001 or not significant with P value more than 0.05, respectively. (C) Efficiency of the fibrils shown
in A in conferring yeast cells with the [PSI+] prion phenotype upon transfection. Yeast cells transfected with the fibrils were replica plated onto 1/4YEPD and
-ade synthetic media to check for the [PSI+] prion phenotype and 1/4YEPD supplemented with 3 mM GdnHCl to eliminate any false positives. The fibrils were
sonicated for 600 s before transfection experiments. Negative [psi−] and positive [PSI+] phenotype controls are indicated on the plate images with red and
white dots, respectively. (D) Quantification and comparison of the transfection efficiency and the [PSI+] phenotype displayed by the yeast cells transfected
with the fibrils shown in A. The bars indicate average values of at least three independent experiments performed on separate days, and the error bars
represent the SE of mean.
Fig. 7. Transfection of yeast cells with Aβ42s results in enhanced [PSI+] conversion. (A) A typical positively converted colony by Aβ42s is shown together with
positive [PSI+] and negative [psi−] phenotype controls on replica plated as well as streaked plates. The cells were plated onto 1/4YEPD and -ade synthetic
media to check for the [PSI+] prion phenotype and 1/4YEPD supplemented with 3 mM GdnHCl to eliminate any false positives. The identity of the colonies is
indicated by the colored dots. (B) SDD-AGE analysis followed by immunoblotting revealed that aggregates of Sup35 were formed in the yeast cells converted
to [PSI+] by Aβ42s transfection. Cell extract of positive [PSI+] and negative [psi−] controls is shown in the left two lanes for comparison. (C) Quantification and
comparison of the transfection efficiency displayed by the yeast cells transfected with Aβ42s seed particles at different particle concentrations produced by
sonication, with the light purple bars indicating average values of at least three independent experiments performed on separate days with the error bars
represent the SE of mean. The right dark gray bar indicates the transfection efficiency displayed by the yeast cells transfected with a cell extract of positive
[PSI+] control (SI Appendix, Fig. S5) for comparison.
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presence of 3 mM GdnHCl) (37). Since the presence of minuscule
amounts of Aβ42s seeds cannot be readily detected due to the slow
conversion rate, the large dilution factor when single particles enter
the cell volume, and when the cell goes on to divide for many cycles
to form colonies, control experiments were carried out to confirm
conversion to [PSI+] by Aβ42s transfection. Firstly, semidenaturing
agarose gel electrophoresis (SDD-AGE) gel assay followed by
immunoblotting were carried out, confirming that the Sup35 pro-
tein were indeed converted to an aggregated state in all tested
[PSI+] cells converted by Aβ42s transfection (Fig. 7B), with the
same pattern compared to Sup35 in cells converted by Sup35NMs
seeds (25). Secondly, the efficiency of transfection and subsequent
conversion to [PSI+] was much less frequent using Aβ42s than
transfection with Sup35NMs particles (25, 31) or in vivo–formed
Sup35 particles (SI Appendix, Fig. S5), but the samples with in-
creasing particle concentration generated through controlled son-
ication of Aβ42s did not significantly increase their efficiency in
conversion of cells to [PSI+] (Fig. 7C), consistent with prediction II
(Fig. 1C). Finally, a control experiment was carried out to compare
the low frequency of [PSI+] occurrence following transfection by
Aβ42s with the frequency of the spontaneous de novo formation of
[PSI+] in the absence of any amyloid seeds. The results show that
the frequency of [PSI+] occurrence was around 1000-fold higher in
yeast cells following transfection by Aβ42s compared to sponta-
neous de novo formation of [PSI+] in nontransfected [psi−] cells
(Table 1).
To confirm that amyloid seeds are capable of acting as pro-
miscuous nano-particles that can promote enhanced heterologous
amyloid formation in vitro and in vivo and this is not limited to
Aβ42s, we tested whether amyloid seed particles formed from
Aβ40 (Aβ40s) possess the same type of seeding capabilities toward
Sup35 in yeast cells, despite the structures of Aβ40 amyloid is very
different to that of Aβ42 amyloid (e.g., refs. 38–40). Analysis of
Sup35NMm amyloid forming reactions seeded with in vitro
formed Aβ40s (SI Appendix, Fig. S6A) confirmed that Aβ40s is
indeed also capable of increasing the rate of Sup35NM amyloid
formation in vitro (SI Appendix, Fig. S6B). Importantly, yeast
transfection experiments carried out using Aβ40s seed samples
demonstrate that they are also able to enhance [PSI+] conversion
of cells in vivo when transfected into [psi−] yeast cells (SI Ap-
pendix, Fig. S6C), with a lower frequency compared with in vivo
formed Sup35 aggregates but comparable to that seen with Aβ42s.
Taken together, these in vivo analyses show that Aβ40s and
Aβ42s particles can increase the appearance of the [PSI+] prion
in vivo when introduced into prion-free [psi−] yeast cells despite
no evident biological or structural links existing between the
yeast Sup35 protein, its maintenance chaperone network in vivo,
and Aβ sequences. These findings are consistent with the pro-
motion of nonnative heterologous surface interactions by Aβ
amyloid particles in vivo as we also observed in vitro and dem-
onstrate that heterologous cross-seeding of amyloid may reflect
the generic property of amyloid seeds and their surfaces in
biological systems.
Discussion
Synergetic heterologous interactions of amyloid aggregates, as
exemplified by amyloid cross-seeding, is a well-known phenom-
enon and frequently studied in relation to human diseases linked
to human amyloidogenic proteins (reviewed in ref. 9). In these
cases, cross-seeding has been assumed to also contribute to why
some amyloid-associated diseases coincide with the formation of
other nonhomologous amyloid aggregates. However, the mo-
lecular mechanism of how such cross-seeding processes proceed
in vitro or in vivo remain unresolved because the widely accepted
templated elongation model does not explain how completely
different sequences and structures are capable of templating each
other. In addition, the importance of primary sequence similarity for
the observed cross-seeding between heterologous protein aggregates
is not clear (e.g., refs. 41, 42). Thus, the current view of cross-seeding
through templated elongation alone does not readily explain the
synergetic statistical links between amyloid diseases associated with
nonhomologous proteins (14–16). Here, under rigorously controlled
conditions, we have investigated the cross-seeding interactions be-
tween two amyloid-forming proteins, namely, human Aβ42 and yeast
Sup35NM. These two proteins were chosen because they are entirely
unrelated in terms of sequence, structure, and biological function
and consequently should not be able to template the elongation
growth of each other. Yet, we observed cross-seeding effects be-
tween these two proteins, in which nonhomologous fibrillar seeds
significantly shortened the lag phase of amyloid-forming reactions,
albeit to a much lesser extent compared to homologous seeds. We
also found that the effect of nonhomologous cross-seeding in the
fibril-forming reaction for these two proteins was not symmetric and
instead depended on the aggregation properties of monomers under
the reaction conditions used (43) and on the specific type of seeds
used. In addition, in vivo studies whereby amyloid seeds can be in-
troduced into a genetically marked strain of S. cerevisiae that reports
the ability of those seeds to trigger the formation of Sup35 amyloid
(31) were carried out. Whereas different in vitro–generated or
extract-purified variants of Sup35NM fibrils when transfected into
such yeast cells are faithfully propagated, creating different ratios of
weak or strong [PSI+] phenotypes (31, 33, 44), Sup35NM fibrils
formed in Aβ42-seeded reaction generated a mixture of [PSI+]
phenotypes that were indistinguishable to those arising when de
novo–formed or self-seeded Sup35NM fibrils generated in vitro were
used (Fig. 6).
The results we obtained for the heterologous seeding action
between these two unrelated amyloidogenic proteins are not
consistent with templated elongation but are entirely consistent
with the amyloid seeds acting as nanoparticles that affect het-
erologous amyloid assembly through surface-based interactions.
In our experiments, both the Aβ42s and Sup35NMs seeds acted
to accelerate the amyloid formation of the other protein, giving
Table 1. Frequency of [PSI+] appearance for yeast cells transfected with Aβ42s compared with
de novo formation of [PSI+] in wild-type S. cerevisiae strains
Strain Frequency of [PSI+] appearance* 95% CI
74D-694 transfected with Aβ42s† 2.2 × 10−2 1.5 × 10−2–2.9 × 10−2
74D-694 Haploid† 1.1 × 10−5 0.1 × 10−5–2.1 × 10−5
74D-694 Diploid† 2.4 × 10−5 1.5 × 10−5–3.2 × 10−5
243/6a‡ 10−7–10−5 —
74D-694§ 5.8 × 10−7 4.6 × 10−7–7.5 × 10−7
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rise to the observed cross-seeding effect without acting as templates
of their own conformation (Fig. 8). However, not all amyloid seeds
are likely to be capable of accelerating amyloid formation for all
amyloid sequences. For amyloid-forming protein pairs that do cross-
interact, the balance between the templated fibril elongation at the
fibril ends and the surface-catalyzed fibril formation pathways is
likely dependent on factors such as the sequence similarity between
the seed and the monomers, the conformational flexibility of the
monomers, the solution conditions, and the surface properties of
individual amyloid seeds. Indeed, heterologous surface catalysis is
often utilized in organic synthesis while amyloid seeding by surface-
catalyzed heterogeneous nucleation or retardation by surface in-
teractions are commonly observed effects of polymeric and non-
polymeric nanoparticles alike (45).
Since nucleated protein assembly catalyzed by seed surfaces is
not dictated by the amyloid conformation of the seeds in the same
way as in templated elongation reactions, the resulting amyloid fi-
brils from surface-catalyzed reactions could have structures distinct
from that of the seeds (Fig. 1, prediction III). Furthermore, the
resulting amyloid structures could be diverse in their morphology.
This is because seeding and cross-seeding through surface-catalyzed
nucleation events may be expected to introduce heterogeneity in the
resulting amyloid aggregates depending on the assembly conditions,
whereas seeding though templating will propagate specific amyloid
conformations and thereby reducing possible heterogeneity. For
amyloidogenic proteins involved in misfolded protein diseases,
heterologous amyloid particles would potentially allow the forma-
tion of a pallet of conformational variants or strains, with different
levels of toxicity and infectious potential (46, 47). Thus, structural
polymorphism (48–50) as a consequence of species heterogeneity
modified by the cross-seeded reaction could lead to the generation
of new toxic conformers, and their propagation could play an im-
portant role in disease.
Previous studies have demonstrated that Aβ42 aggregation is
accelerated by an auto-catalyzed nucleation process. In common
with the cross-seeding mechanism we address here, this autocata-
lytic process of secondary nucleation is a surface-driven process
(21) and is one of the major processes involved in homologous
amyloid assembly (Fig. 1). Thus, the surfaces of preformed amyloid
seeds of Aβ42, even outside of active elongation sites at fibril ends
(51), appear to be particularly active and capable of accelerating
formation of new amyloid through promoting surface interactions.
The secondary nucleation mechanism can accelerate amyloid for-
mation as well as to generate small oligomeric species that could be
biologically active in driving the toxic potential of Aβ42 amyloid
(21). This suggests that the surfaces of small Aβ42 amyloid seeds,
as nanoparticle surfaces, may be able to act as general amyloid
formation catalysts for both homologous and heterologous se-
quences and, in the process of accelerating heterologous amyloid
formation, generate some species that may possess cytotoxic po-
tential. Interestingly, recent research has shown that for another
yeast prion-forming protein Ure2, the surface-catalyzed secondary
nucleation process does not dominate homologous assembly in
presence of preformed fibrils (52). It has been suggested that the
absence of secondary nucleation results in a reduced generation of
toxic oligomeric species and therefore lower toxicity associated
with formation and propagation of yeast prions. In contrast, a
secondary nucleation mechanism has been inferred in cases in-
volved in the amyloid formation of peptides and proteins associ-
ated with neurodegenerative diseases and type 2 diabetes (e.g.,
Aβ42, Aβ40, a-synuclein, IAPP, and insulin; reviewed in ref. 53).
Thus, the generation of such amyloidogenic species with height-
ened toxic potential may depend on the surface properties of the
seed particles and how these surfaces interact with both homolo-
gous and heterologous monomeric protein sequences that are
present in the same biological milieu.
The enhanced likelihood of generating the Sup35-based
[PSI+] prion upon transfection of prion-free [psi−] cells with
Aβ42 fibril particles is consistent with our hypothesis that amy-
loid seeds as nanoparticles can influence the formation of het-
erologous amyloid via aberrant surface interactions. The
presence of aberrant surfaces such as those presented by Aβ42
fibril particles in yeast cells may also act through modulating
cellular proteostasis. This could therefore subtly affect the bal-
ance of proteins such as the molecular chaperones critical for the
prion generation and propagation pathways (e.g., the AAA+-
ATPase Hsp104) (54–56). Thus, Aβ42 fibril particles in vivo may
provide surface-mediated interactions accelerating the formation
Fig. 8. Schematic illustration of a cross-seeding mechanism involving surface-catalyzed heterogeneous nucleation by amyloid particles acting as promiscuous
nanoparticles with active surfaces that also promote secondary nucleation. The surface-catalyzed cross-seeding is represented by the green arrows that links
the lifecycles of two otherwise unrelated amyloid systems represented as black and green monomeric units, respectively. Sites for templated growth and
surfaces for secondary nucleation or cross-seeding by surface-catalyzed nucleation are highlighted in red and purple, respectively. All arrows represent
dynamic and reversible steps along the lifecycle and the thickness of the arrows illustrate typical relative magnitudes of the rates involved in each of the
processes.
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and the propagation of the amyloid state in the cells though
direct as well as indirect modes of action. These insights bring to
the fore surface properties and surface interactions of amyloid
particles as a key mesoscopic property to target in order to un-
derstand the origin of the amyloid cytotoxic potential and the
synergetic link between different amyloid diseases as well as
designing therapies to combat the disease processes associated
with toxic amyloid.
Materials and Methods
Terminology. Fibrillar seed particles of Aβ42 and Sup35NM used in the ex-
periments are referred to as Aβ42s and Sup35NMs, respectively. The mo-
nomeric precursors of respective amyloid used in the experiments are
referred to as Aβ42m and Sup35NMm, respectively. The terms Aβ42 and
Sup35NM are used to refer to general aspects of the proteins or to the as-
sembly of the respective amyloid.
Protein Expression and Purification. Sup35NM protein samples were produced
as described previously (25) with minor changes as follows. The DNA se-
quence encoding the N-terminal NM region of the yeast Sup35 protein
(residues 1 through 254) was amplified from plasmid pUKC1620 by PCR and
cloned into pET15b as a BamHI-NdeI fragment, resulting in an N-terminal
His6-tag fusion protein. The resulting plasmid (pET15b-His6-NM) was then
transformed into the E. coli strain BL21 DE3 (F– ompT gal dcm lon hsdSB(rB-
mB-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]). For protein expression,
this E. coli strain was grown overnight in 50 mL Lysogeny broth (LB) sup-
plemented with 0.1 mg/mL ampicillin and then transferred to 1-L cultures of
the same medium. On reaching an optical density at 600 nm (OD600) of ∼0.5,
expression was induced by the addition of isopropyl ß-D-1-thiogalactopyr-
anoside (1 mM final concentration) for 4 h. Cells were harvested at 6,000 rpm,
and the cell pellets washed once in buffer A1 (20 mM Tris·HCl pH 8.0, 1 M NaCl,
and 20mM imidazole). Cells were pelleted again and the pellets kept at−80 °C
for later use. For the affinity purification step, buffer A2 (20 mM Tris·HCl pH
8.0, 1 M NaCl, 20 mM Imidazole, and 6 M GdnHCl) was added to frozen cell
pellets at a 5:1 (vol/vol) ratio, followed by sonication at an amplitude of 22
microns until the cell pellet was completely disrupted. This solution was then
spun down at 13,000 rpm for 30 min and the supernatant collected. A total of
2 mL of Chelating Sepharose Fast Flow (GE Healthcare) was added to a small
plastic column and prepared for affinity purification by sequential washing
with 1 column volume (CV) of water, 0.2 M NiCl2, buffer A1, and buffer A2.
The equilibrated resin was then resuspended in buffer A2 and added to pre-
viously collected supernatant. This mixture was then incubated for 1 h at room
temperature with agitation to improve protein binding to the affinity resin.
Centrifugation at 5,000 rpm was subsequently used to collect the resin, which
was then washed in 5 mL buffer A2, resuspended in buffer A2, and transferred
back to the column. After one wash with 1 CV buffer A2, elution was achieved
by addition of 3 mL buffer A3 (20 mM Tris·HCl pH 8.0, 1 M NaCl, 0.25 M im-
idazole, and 6 M GdnHCl). The resulting eluate was immediately used for size-
exclusion purification, which was run using a HiLoad 16/600 Superdex 200 pg
(GE Healthcare) column in an ÄKTA Prime Plus chromatography system (GE
Healthcare). The eluate was injected into the size-exclusion column previously
equilibrated with 1 CV water followed by 1 CV buffer S1 (20 mM Tris·HCl pH
8.0, and 0.5 M NaCl) and 1 CV buffer S2 (20 mM Tris·HCl pH 8.0, 0.5 M NaCl,
and 6 M GdnHCl). The relevant Sup35NM protein fractions were collected
according to the A280 displayed throughout the run, diluted to 20 μM in buffer
S2, and immediately used in fibril-forming reactions.
The Amyloid Beta (1-42) peptide (Aβ42) and Amyloid Beta (1-40) peptide
(Aβ40) was purchased in 5-mg batches from Bachem (Germany). This was
aliquoted in 0.5-mg stock batches and frozen at −20 °C. Monomers were
further purified as described previously (23, 24) with minor modifications.
Briefly, the Aβ42 was purified using gel filtration as follows: 0.5 to 1 mg of
Aβ42 was dissolved in 1 mL 6 M GdnHCl. This was loaded onto a Superdex
75 10/300 GL column pre-equilibrated with 2 CV of 20 mM sodium phos-
phate, pH 7.4, and 0.01% NaN3 (buffer E). The monomer peak was eluted
with buffer E and put on ice. The concentration was then determined using
ultraviolet spectroscopy (280 nm) and adjusted to working concentration of
10 μM with buffer E before immediately proceeding with fibril-forming re-
actions. The Aβ40 was purified using gel filtration using the same procedure.
Fibril Formation and Monitoring. For Sup35NM fibril formation, 2.5 mL of
20 μM purified Sup35NM were buffer-exchanged into Fibril Forming Buffer
(FFB; 20 mM sodium phosphate buffer pH 7.4, 50 mM NaCl) using a PD-10
column (GE Healthcare) as per the manufacturer’s instructions. Unless oth-
erwise specified, protein concentration was measured using A280 and then
adjusted to 10 μM using FFB. Protein samples were aliquoted into Protein
LoBind tubes (Eppendorf) and polymerized at 30 °C quiescently for at least
48 h. For monitoring polymerization, 100-μL samples of protein were ali-
quoted into black low-binding hydrograde 96-well plates (BRAND), and ThT
was added to a final concentration of 10 μM. The plate was sealed with
Starseal Advanced Polyolefin Film (Starlab), and kinetics were monitored in a
96-well format (3) using a FLUOstar OMEGA plate reader (BMG Labtech)
quiescently at 30 °C.
For Aβ42 and Aβ40 fibrils assembly reaction, a 10-μM solution of mono-
mers purified as described above was either aliquoted either into Protein
LoBind tubes or into black hydrograde 96-well plates (BRAND) with 10 μM of
ThT for kinetic monitoring using identical method as described above
for Sup35NM.
The fibril assembly reaction traces were analyzed in Matlab. At least nine
replicate reaction traces from three independent experiments performed
using independent protein samples prepared on different days were col-
lected. For each trace, the length of the lag phase (tlag) and the initial slop
(k0), both indicative of early processes of seeded amyloid assembly reactions,
were extracted using the method illustrated in SI Appendix, Fig. S3. For the
analysis of the tlag values, one-way ANOVA with Tukey’s Honestly Significant
Difference Procedure was carried out for statistical multiple pair-wise com-
parison to determine whether the length of the lag phase was significantly
different or not to unseeded reactions. Global analysis was carried out with
numerical solutions of SI Appendix, Eq. S4 obtained using ordinary differential
equation solvers in Matlab. Uncertainties in the fitted kinetic parameters were
estimated using a Bootstrap method with 500 resampled datasets.
Fibril Fragmentation. Fibril fragmentation was achieved by sonication over
different periods of time using a probe sonicator (Qsonica Q125) at 20%
amplitude in consecutive 5-s on/off cycles on an ice-cooled water bath.
DLS. All vials, tubes, and cuvettes used for preparing the samples were clean
dry. All solvents used were filtered to remove any particulates that may
interfere with the results obtained. The Aβ42 or Sup35NM fibril seed samples
obtained after controlled sonication were diluted 10 times using the same
FFB as in the fibril formation experiments. The samples were subsequently
characterized by DLS at 25 °C using an Anton Paar Litesizer 500 instrument
and the data processed using KalliopeTM Professional.
Yeast Transfection with Amyloid Fibrils. For yeast transfection with Sup35NM
synthetic amyloid fibrils, a [psi−] derivative of the yeast strain 74D-694 (MATα
ade1-14 trp1-289 his3Δ-200 ura3-52 leu2-3,112), and [PIN+] derivative of the
same strain was used for transfections of Aβ42 fibrils. The transfection
procedure was as previously described (25). Briefly, cells freshly grown in
YEPD to an OD600 of 0.5 were washed, resuspended in 12 mL ST buffer (1 M
sorbitol, 10 mM Tris·HCl pH 7.5), and spheroplasts were prepared by addition
of 600 U of lyticase (Sigma L4025) and 10 mM DTT during incubation at 30 °C
with agitation for 45 min. Spheroplasts were then harvested by centrifu-
gation (400 g, 5 min), washed with 1.2 M sorbitol and STC buffer (1.2 M
Sorbitol, 10 mM Tris·HCl pH 7.5, and 10 mM CaCl2), and then resuspended in
1 mL STC buffer. Premixture of 2 μL (∼1 μg) of plasmid DNA (pRS416), 10 μL
single-stranded DNA (10 mg/mL), and 10 μL of freshly sonicated amyloid fi-
brils (described in the Fibril Fragmentation section) were combined with
100 μL spheroplast suspension for each transformation reaction. This trans-
formation mix was then incubated for 10 min at room temperature, and
then 0.9 mL of polyethylene glycol buffer (40% PEG 4000, 10 mM Tris·HCl pH
7.5, and 10 mM CaCl2) was added to each transformation. After 30 min at
room temperature, the spheroplasts were collected by centrifugation (400 g,
5 min), resuspended in 200 μL SOS media (1 M Sorbitol, 25% YEPD, 10mM
CaCl2), and added to sterile Top agar (-uracil synthetic complete media with
2% agar and 1.2 M Sorbitol) being kept at 48 °C, gently mixed, and then
poured into agar plates previously prepared using the same media. Cells
were allowed to grow for 3 to 4 d at 30 °C, and then colonies were indi-
vidually picked into 96-well plates containing YEPD (yeast extract 1%, bac-
topeptone 2%, glucose 2%, and agar 2%). These were grown overnight at
30 °C with agitation and then replica plated onto 1/4YEPD (0.25%, bacto-
peptone 2%, glucose 2%, and agar 2%) and -ade synthetic media to check
for the [PSI+] prion phenotype and 1/4YEPD supplemented with 3 mM
GdnHCl to eliminate any false positives as 3 mM GdnHCl eliminates the [PSI+]
prion (37). Fragmented amyloid fibrils used in transfection experiments were
simultaneously prepared for imaging analysis using AFM as described in the
AFM Analysis section. [PSI+] cells arising from transfections with Aβ42 fibrils
typically generated colonies consisting of a mixture of white wand red cells.
In such cases, the white colonies were subcloned on 1/4YEPD and -ade plates
and rechecked for their [PSI+] prion phenotype on 1/4YEPD+GdnHCl plates.
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Preparation of Cell Extracts and SDD-AGE. Cell extracts were prepared by first
harvesting yeast cells (∼2 × 107 cells) and resuspending the pellet in 100 μL
PEB buffer (25 mM Tris·HCl pH 7.5, 50 mM KCl, 10 mM MgCl2, 1 mM EDTA,
and EDTA-free Protease Inhibitor Mixture [Roche]). Approximately 1 pellet
volume of small glass beads was added to the resuspended cells and lysis
performed by vortexing at 4 °C. The lysate was then cleared by centrifuga-
tion (8,000 rpm, 10 min, 4 °C), and total protein concentration in the col-
lected clear lysate was measured at A280. SDD-AGE analysis was performed
as previously described (57). Briefly, ∼100 μg total protein were loaded per
lane. Samples were loaded in a 1.5% agarose gel prepared in buffer G
(20 mM Tris, 200 mM glycine) and ran in Laemmli buffer (20 mM Tris,
200 mM glycine, and 0.1% SDS). Proteins were transferred using semidry
blotting and transfer buffer T (20 mM Tris, 200 mM Glycine, 0.1% SDS, and
15% [vol/vol] methanol) onto a polyvinylidene difluoride (PVDF) membrane
for 90 min at 10 V. The anti-Sup35 primary antibody MT50 was used in
Western blot analysis as described previously (25).
Quantification of Spontaneous De Novo Appearance Frequency of [PSI+]. The
frequency of spontaneous de novo conversion of yeast cells from [psi−] to
[PSI+] was quantified using an adaptation of a previously published protocol
(58). Here, the [psi−][PIN+] derivative of the strain 74-D694 was used. A total
of 10 independent and freshly grown colonies were randomly selected from
YEPD plates and grown in YEPD media to reach an OD600 of 0.5. The cells
were then washed, resuspended in sterile water, and plated on -ade medium
at three dilutions (around 105 cells/plate, 104 cells/plate, and 103 cells/plate)
to ensure that the residual growth on -ade plates does not affect the ap-
pearance of Ade+ colonies. To determine the concentration of viable cells,
an aliquot of each culture was used for a serial dilution plated on YEPD
medium. Ade+ colonies were counted on -ade plates after 10 d of growth at
25 °C. To confirm [PSI+] phenotype, the Ade+ colonies were replica-plated on
GdnHCl media and characterized further by SDD-AGE for confirming the
presence of SDS-resistant Sup35 aggregates. For the Aβ42-transfected cells,
colonies selected on -ura plates 3 d after transfection were grown overnight
in YEPD media and stamped on –ade, 1/4YEPD, and 1/4YEPD media con-
taining 3 mM GdnHCl. [PSI+] formation rates were calculated according to
the formula R = f/ln(NR), where R is the rate of [PSI+] formation, f is the
observed frequency of [PSI+] colonies, and N is the number of cells in the
culture (58, 59).
AFM Analysis. The fibril samples were diluted 1:100 for Sup35NM, and 20-μL
droplets were deposited on freshly cleaved mica discs (Agar Scientific F7013).
After 10-min incubation at room temperature, excess sample was removed by
washing with 1 mL of 0.2-μm syringe-filteredmQH2O, and the specimens were
then dried under a gentle stream of N2(g). For Aβ42 fibrils, samples were di-
luted 1:10, and 10 μL were deposited on mica disk, let dry at room tempera-
ture, washed with 500 μL of mQ H2O, and then dried under a gentle stream of
N2(g). Samples were imaged using a Bruker Multimode AFMwith a Nanoscope
V controller and a ScanAsyst probe (Silicone nitride tip with nominal tip ra-
dius = 2 nm, nominal spring constant 0.4 N/m, and nominal resonant fre-
quency 70 kHz). Images were captured at a resolution of 4.88 nm per pixel
scanned. All images were processed using the Nanoscope analysis software
(version 1.5, Bruker). The image baseline was flattened using third order
baseline correction to remove tilt and bow. Processed image files were opened
and analyzed using automated scripts written in Matlab (60).
Data Availability.All study data are included in the article and/or SI Appendix.
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